News

Pharmaceutical Technology on MSN3d
FDA accepts Novo Nordisk’s NDA submission for weight management therapy
The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...
Pharmabiz3d
US FDA accepts Novo Nordisk’s NDA submission for oral semaglutide 25 mg for treatment of obesity
Novo Nordisk ... to once-daily oral semaglutide 25 mg or placebo, as an adjunct to lifestyle intervention for 64 weeks. The FDA action date to decide on the Wegovy oral formulation NDA will be in Q4 ...
The American Journal of Managed Care7d
Novo Nordisk Expands GLP-1 Access Through Telehealth Providers
Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...
NJBIZ2d
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Managed Healthcare Executive9d
Novo Nordisk Offers Wegovy Through Telehealth Providers, Including Hims & Hers
Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...
The Victoria Advocate9d
Novo Nordisk expands patient access to authentic, FDA-approved Wegovy® via collaborations with multiple telehealth organizations
PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding patient access to Wegovy ® (semaglutide) injection 2.4 mg by enabling select telehealth providers ...
Yahoo Finance3d
FDA accepts Novo Nordisk’s NDA submission for weight management therapy
The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy (semaglutide) intended for chronic weight ...